Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported positive top-line results from its Phase 2b STORM study evaluating the activity of selinexor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trader Talk Trading Halts

Baird Maintains Bullish View on Karyopharm Therapeutics (KPTI) Following Positive STORM ResultsSeptember 6, 2016 10:08 AM Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple MyelomaSeptember 6, 2016 7:00 AM